GLP-1 Insurance Coverage Guide 2026: Commercial, Medicare, and Medicaid

Whether insurance covers your GLP-1 drug depends on three variables that interact in non-obvious ways: what the drug is approved for, who your insurer is, and whether the drug's therapeutic indication matches the coverage decision your plan has made.

This reference covers the current coverage picture across commercial, Medicare, and Medicaid payers.

The indication split: T2D vs obesity

The same active molecules — semaglutide and tirzepatide — are sold under different brand names for different approved uses:

Insurance coverage for T2D is structurally different from obesity coverage. T2D has been a covered chronic condition for decades; treatment protocols are established and formularies are built. Obesity as a primary indication for expensive pharmacotherapy is a newer policy question, and many payers have not yet fully resolved it.

Commercial insurance (employer-sponsored plans)

T2D indication: Most commercial plans cover Ozempic, Mounjaro, Rybelsus, and similar T2D GLP-1s. Prior authorisation requirements exist but are usually satisfied with documented T2D diagnosis and failure on metformin.

Manufacturer savings cards reduce out-of-pocket for commercially insured T2D patients:

• Mounjaro Savings Card: as low as $25/month
• Ozempic SteadyStart: as low as $25/month
• Not available for Medicare, Medicaid, or Tricare

Obesity indication: As of 2025, approximately 49% of employers with 500+ employees covered obesity-indicated GLP-1s (Wegovy, Zepbound). Among all employers (including small), coverage is lower. The plans that cover them typically require:

• BMI ≥30 or BMI ≥27 with documented comorbidity (see our GLP-1 eligibility criteria guide for the full label criteria)
• Prior authorisation
• Step therapy (documenting failure on lower-cost options)
• Sometimes: participation in a supervised weight-loss programme

Prior authorisation approval timelines typically run 2–12 weeks. The step therapy guide covers the full PA process.

ERISA vs fully-insured plans: Large employers often self-fund their health plan (ERISA plan) with an insurer administering it. ERISA plans are not subject to state insurance mandates, including state-level step therapy override laws. Approximately 65% of covered workers are in self-funded plans.

Medicare

Part D (prescription drug coverage):

Medicare GLP-1 Bridge (effective July 1, 2026):

CMS launched the Medicare GLP-1 Bridge as an 18-month demonstration programme. Key details:

• Covers: Zepbound KwikPen only (not Wegovy, not vials, not other GLP-1 brands)
• Eligibility: Medicare patients with obesity (BMI ≥30 or ≥27 + weight-related condition) — T2D not required
• Copay: $50/month
• Duration: 18 months (demonstration, not a permanent benefit)
• Prior authorisation: may still be required by your specific Part D plan

Dual-eligible patients (Medicare + Medicaid): Medicare is primary payer; Medicaid may provide cost-sharing assistance, potentially reducing the $50 copay further.

Medicare Supplement (Medigap) plans: Most Medigap plans do not cover outpatient drugs — Part D is the drug coverage layer.

Medicaid

Medicaid GLP-1 coverage for obesity is a state-by-state decision. As of 2026:

• ~13 states cover Wegovy or Zepbound for obesity on Medicaid (including California, Illinois, Massachusetts, New York, others)
• Most states do not cover obesity-indicated GLP-1s; they cover T2D-indicated drugs for T2D patients

Manufacturer savings programmes explicitly exclude Medicaid patients. Self-pay options (NovoCare $349/month, LillyDirect $299–449/month, compounded options) are available to Medicaid patients as cash-pay purchases — Medicaid will not reimburse these.

Full Medicaid coverage analysis: Medicaid GLP-1 coverage guide.

Tricare (military and dependents)

Tricare covers GLP-1s for T2D. Coverage for obesity varies by Tricare programme (Tricare Prime vs Select vs for Life). Manufacturer savings cards do not apply to Tricare patients.

What to do if your plan doesn't cover GLP-1s for obesity

Step 1: Verify the specific plan's current formulary. Insurance formularies change annually and sometimes mid-year. Plans that excluded Wegovy in 2024 may have added it in 2025 or 2026. Request the current formulary criteria document.

Step 2: File prior authorisation. Even if prior approval seems unlikely, filing creates an administrative record for appeal and establishes the PA date if coverage is later added.

Step 3: Appeal. PA denials can be appealed. External review rights exist in most states for fully-insured plans. ERISA plans also have appeal rights (Department of Labor oversight). Our prior authorization appeal guide covers the full step-by-step process.

Step 4: Self-pay options while appealing. Compounded GLP-1s (~$178–229/month) or NovoCare/LillyDirect ($299–449/month) can provide access during the coverage gap. See our how to get a GLP-1 prescription guide for navigating the prescription process alongside insurance filing.

Telehealth platforms that actively manage the PA and appeals process: Form Health, Calibrate, Mochi Health, Ro Body.